Source: Eur Respir J 2015; 45: 1741-1744
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Honeyborne Isobella, Lipman Marc C., Eckold Clare, Evangelopoulos Dimitrios, Gillespie Stephen H., Pym Alexander, McHugh Timothy D.. Effective anti-tuberculosis therapy correlates with plasma small RNA. Eur Respir J 2015; 45: 1741-1744

Member's Comments

No comment yet.

Related content which might interest you: Timing of concurrent highly active antiretroviral therapy (HAART) in adults with tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 302s Year: 2006 Better diagnostics for targeted antibiotic therapy Source: Virtual Congress 2020 – Antibiotic resistance: the way forward Year: 2020 Current antiretroviral therapy Source: Eur Respir Monogr 2014; 66: 12-25 Year: 2014 Optimizing the target therapy development Source: ERS Research Seminar Year: 2015 Paradoxical response to adequate antituberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004 Plasma DNA concentration and integrity measurement for NSCLC diagnostics and radical therapy effectiveness monitoring Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis Source: ISSN=ISSN 1810-6838, ISBN=, page=69 Year: 2007 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020 Comparison of anti-tuberculosis regimens using fixed dose combination versus single drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Convalescent plasma therapy in COVID-19 patients: Chinese and European perspectives Source: ERS webinar 2020: Convalescent plasma therapy in COVID-19 patients: Chinese and European perspectives Year: 2020 Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Characteristics of patients who interrupted anti-tuberculosis treatment Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 The role of serum rifampicin level on antituberculosis treatment outcome Source: Eur Respir J 2006; 28: Suppl. 50, 848s Year: 2006 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Concomitant radiotherapy and targeted therapies Source: International Congress 2019 – New perspectives in thoracic surgical oncology Year: 2019 Long-term antibiotic therapy Source: International Congress 2017 – PG3 Bronchiectasis Year: 2017 The effect of anti-tuberculosis chemotherapy using second-line drugs on the structural and functional state of the thyroid gland Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012